Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exagen Inc. - Common Stock
(NQ:
XGN
)
5.150
+0.440 (+9.34%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exagen Inc. - Common Stock
< Previous
1
2
Next >
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
December 12, 2024
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
November 14, 2024
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 13, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. (NASDAQ: XGN) Near the Top of Equities by Percentage Gain on 1/29
January 29, 2024
Via
Investor Brand Network
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
October 29, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
October 21, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
September 04, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
August 05, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 02, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
August 01, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
July 22, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
May 13, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Announces Campaign for Lupus Awareness Month
May 06, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce First Quarter 2024 Results on May 13, 2024
April 30, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Changes to the Board of Directors
April 26, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
March 18, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 08, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
March 07, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 30, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
January 07, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Third Quarter 2023 Results
November 13, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
November 09, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
November 02, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
October 30, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
September 28, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 12, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Second Quarter 2023 Results
August 07, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 26, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 25, 2023
From
Exagen Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
